FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHAN	GES IN BE	NEFICIAL (	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bure	den								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Daniels Mark  (Last) (First) (Middle)  C/O TWIST BIOSCIENCE CORPORATION  681 GATEWAY BLVD.					3. Da	2. Issuer Name and Ticker or Trading Symbol Twist Bioscience Corp [ TWST ]  3. Date of Earliest Transaction (Month/Day/Year) 02/04/2021  5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) See Remarks										wner specify				
(Street) SOUTH SAN FRANCISCO  (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indi Line) X						
		Tahl	e I - No	n-Deriv	ativo	Sec	uritia		auire	4 D	snoso	d 0	of or Be	nefic	ially	Owner	1			
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transact Date (Month/Date)			tion 2A. Deemed Execution Date,		3. 4. Securi Disposed Code (Instr.		uriti	es Acquire Of (D) (Ins	ed (A) o	5. Amor and 5) Securiti Benefic Owned		nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership					
								Cod	e v	Amour	nt	(A) or (D)	Pric	е	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 02/04/2				2021		M	$\top$	66	668		\$1	10.7	68	3,868		D				
Common Stock 02/04/2			2021			<b>S</b> <sup>(1)</sup>		66	8	D \$1		91.52	2 68,200			D				
		Т	able II -										or Ben ble sec			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	ate, Transac Code (Ir				6. Date Expira (Month		ar)		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiratio Date	n	Title	Amou or Numb of Share	er					
Employee Stock Option (right to buy)	\$10.7	02/04/2021			М			668	(2)		02/01/202	28	Common Stock	66	3	\$0	7,354		D	

## **Explanation of Responses:**

- 1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 15, 2020.
- 2. The option is immediately exercisable. 25% of the shares subject to the option vest on January 1, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

## Remarks:

Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer, and Secretary

/s/ William Solis, as Attorneyin-Fact for Mark Daniels

02/08/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.